NCT02472886 - Safety and Efficacy of Ledipasvir/Sofosbuvir in Adults With Chronic HCV Infection | Biotech Hunter

Enrollment

153

Participants

Timeline

Start Date

June 17, 2015

Primary Completion Date

March 30, 2016

Study Completion Date

June 30, 2016

Conditions

Hepatitis C Virus Infection

Interventions

DRUG

LDV/SOF

90/400 mg FDC tablet administered orally once daily

DRUG

RBV

Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)

Trial Locations (20)

10167

Tallinn

51014

Tartu

105275

Moscow

107014

Moscow

111123

Moscow

115446

Moscow

117593

Moscow

119435

Moscow

119991

Moscow

125367

Moscow

127015

Moscow

129090

Moscow

129110

Moscow

190103

Saint Petersburg

194044

Saint Petersburg

355017

Stavropol

443063

Samara

620102

Yekaterinburg

625026

Tyumen

660049

Krasnoyarsk